Becton, Dickinson and Company (BDX) Shares Sold by Pictet Asset Management Ltd.

Pictet Asset Management Ltd. lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 221,336 shares of the medical instruments supplier’s stock after selling 25,068 shares during the period. Pictet Asset Management Ltd. owned about 0.10% of Becton, Dickinson and worth $43,371,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Westchester Capital Management Inc. raised its stake in Becton, Dickinson and by 1.9% in the third quarter. Westchester Capital Management Inc. now owns 40,709 shares of the medical instruments supplier’s stock worth $7,977,000 after buying an additional 746 shares in the last quarter. First Manhattan Co. raised its stake in Becton, Dickinson and by 1.3% in the third quarter. First Manhattan Co. now owns 22,256 shares of the medical instruments supplier’s stock worth $4,361,000 after buying an additional 278 shares in the last quarter. Doyle Wealth Management raised its stake in Becton, Dickinson and by 14.8% in the third quarter. Doyle Wealth Management now owns 2,600 shares of the medical instruments supplier’s stock worth $510,000 after buying an additional 335 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. raised its stake in Becton, Dickinson and by 0.3% in the third quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 89,209 shares of the medical instruments supplier’s stock worth $17,481,000 after buying an additional 281 shares in the last quarter. Finally, Aperio Group LLC raised its stake in Becton, Dickinson and by 3.2% in the third quarter. Aperio Group LLC now owns 176,737 shares of the medical instruments supplier’s stock worth $34,632,000 after buying an additional 5,448 shares in the last quarter. 86.70% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research note on Tuesday, October 31st. Cowen and Company reissued an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Finally, Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $213.47.

In other news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock worth $15,242,688 over the last three months. Corporate insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Shares Sold by Pictet Asset Management Ltd.” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/11/05/becton-dickinson-and-company-bdx-shares-sold-by-pictet-asset-management-ltd.html.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $224.41 on Friday. The firm has a market cap of $51,067.86, a price-to-earnings ratio of 23.65, a PEG ratio of 1.78 and a beta of 1.04. The company has a current ratio of 5.56, a quick ratio of 5.01 and a debt-to-equity ratio of 1.48. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $224.89.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.12 earnings per share. analysts predict that Becton, Dickinson and Company will post 10.6 EPS for the current fiscal year.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit